PLN and type 2 diabetes mellitus: In this review, we aim to discuss what is currently known about the PLN/SERCA2a microdomain in the obese and T2D heart in the context of HFpEF, and to highlight any obstacles and limitations that need to be overcome in order to direct this research field and potential new HFpEF therapies in the future.